METHOD FOR ASSESSING EFFICACY OF DRUG "LAENNEC" ON PHARMACOLOGICAL MODEL OF NON-ALCOHOLIC FATTY LIVER DISEASE WITH IRON OVERLOAD IN EXPERIMENTAL ANIMALS Russian patent published in 2025 - IPC G01N33/68 G09B23/28 G01N33/49 G01N33/70 G01N33/84 G01N33/90 A61K35/50 A61P1/16 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to hepatology, experimental medicine, and can be used to assess the effectiveness of the drug Laennec on a pharmacological model of non-alcoholic fatty liver disease with iron overload in experimental animals – rats. Intraperitoneal introduction of iron sulphate (II) heptahydrate (C.P.) in dose of 50 mg/kg/day, in conditions of oral excessive consumption of solid fraction of palm oil in dosage of 30 g/kg/day and fructose solution in amount of 1 g/kg/days for 12 days. Then the preparation Laennec is introduced in dose of 0.6 ml/kg of body weight per day, intramuscularly, for 4 weeks. That is followed by a biochemical and general blood test. At indicators: ferritin from 127 to 175 mcg/l, transferrin saturation with iron from 25 to 39% and iron in blood serum from 20 to 30 mcmol/l, AST from 115.3 to 222.3 U/l, ALT from 30.4 to 46.6 U/l, leukocytes from 1.9×10⁹ to 7.7×10⁹ cells/l, thrombocytes from 547.6×10⁹ to 734.4x10⁹ cells/l, total protein from 53.5 to 61.7 g/l, creatinine from 27 to 30.6 mcmol/l and GFR from 165 to 178.2 ml/min/1.73 m², Laennec therapy is considered to be effective.

EFFECT: method provides the possibility of proving the efficacy of using a standardized human placenta hydrolyzate of the drug Laennec by assessing the efficacy of Laennec on a histologically confirmed model of non-alcoholic fatty liver disease with multiple organ pathology in rats, caused by the combined intake of excess fats – palm oil, carbohydrates – fructose and inorganic iron – iron sulphate, using evidence in the form of changes in clinical, biochemical, general blood test values and histological markers.

1 cl, 21 dwg, 9 ex